REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2020.10.16 | 13:30 | Permanent Information Releases / General Company News

puce Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol - HTML (w)

2020.10.01 | 07:15 | Permanent Information Releases / General Company News

puce Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement - HTML (w)

2020.09.23 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program - HTML (w)

2020.09.19 | 16:25 | Permanent Information Releases / General Company News

puce Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation - HTML (w)

2020.09.19 | 16:20 | Permanent Information Releases / General Company News

puce Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma - HTML (w)

2020.09.16 | 23:02 | Permanent Information Releases / General Company News

puce Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM - HTML (w)

2020.09.16 | 16:24 | Permanent Information Releases / General Company News

puce Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond - HTML (w)

2020.09.14 | 12:15 | Permanent Information Releases / General Company News

puce European Medicines Agency (EMA) approves safety label update for Novartis Beovu® - HTML (w)

2020.09.14 | 07:15 | Permanent Information Releases / Sales and Revenues

puce Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) - HTML (w)

2020.09.11 | 17:05 | Permanent Information Releases / General Company News

puce Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) - HTML (w)

2020.09.11 | 17:00 | Permanent Information Releases / General Company News

puce Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis - HTML (w)

2020.09.08 | 07:15 | Permanent Information Releases / General Company News

puce Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum - HTML (w)

2020.09.07 | 07:15 | Permanent Information Releases / General Company News

puce Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings - HTML (w)

2020.09.01 | 07:00 | Permanent Information Releases / General Company News

puce Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality - HTML (w)

2020.08.30 | 08:30 | Permanent Information Releases / General Company News

puce Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1360